Our Pipeline

Robust Pipeline Focused on Advancing ROCK Inhibitor Portfolio

Our Pipeline

Target/Product

Indications

Research

Preclinical

Phase 1

Phase 2

Status / Rights

Proprietary

Fibrostenotic Crohn’s Disease

Phase 2 study preparation
Ongoing

DDR Inhibitor Programme

Kidney, lung and liver fibrosis

IND/CTA submission
2027

To be partnered

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Idiopathic pulmonary fibrosis, Interstitial lung disease

Phase 2a data reported

ROCK2 Selective Inhibitor
zelasudil (RXC007)

MASH, Cancer-associated fibrosis

Phase 1b/2 ready

Porcupine Inhibitor
Zamaporvint (RXC004)

Wnt-ligand driven GI-tumours – combination

Data reported
Partnership candidate

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Undisclosed non-oncology

Pan-RAF Inhibitor
(JZP815)

Oncology

KRAS Inhibitors
(Pan-KRAS)

Oncology

CTA: Clinical trial application; DDR1: Discoidin Domain Receptor 1; GI: Gastrointestinal; IND: Investigational new drug application; MASH: Metabolic dysfunction–associated steatohepatitis; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase

Proprietary
Phase 1

Fibrostenotic Crohn’s Disease

STATUS / RIGHTS

Phase 2 study preparation
Ongoing

DDR Inhibitor Programme

Research

Kidney, lung and liver fibrosis

STATUS / RIGHTS

IND/CTA submission
2027

To be partnered

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Phase 2

Idiopathic pulmonary fibrosis, Interstitial lung disease

STATUS / RIGHTS

Phase 2a data reported

ROCK2 Selective Inhibitor
zelasudil (RXC007)

Phase 1

MASH, Cancer-associated fibrosis

STATUS / RIGHTS

Phase 1b/2 ready

Porcupine Inhibitor
Zamaporvint (RXC004)

Phase 2

Wnt-ligand driven GI-tumours – combination

STATUS / RIGHTS

Data reported
Partnership candidate

Partnered

Porcupine Inhibitor
(RXC006/AZD5055)

Phase 1

Undisclosed non-oncology

Pan-RAF Inhibitor
(JZP815)

Phase 1

Oncology

KRAS Inhibitors
(Pan-KRAS)

Preclinical

Oncology

CTA: Clinical trial application; DDR1: Discoidin Domain Receptor 1; GI: Gastrointestinal; IND: Investigational new drug application; MASH: Metabolic dysfunction–associated steatohepatitis; RAF: Rapidly accelerated fibrosarcoma; ROCK: Rho associated protein kinase